RDY
Dr. Reddy’s Laboratories Ltd ADR
NYSE: RDY · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$13.43
+0.00% today
Updated 2026-06-05
Market cap
$11.13B
P/E ratio
24.76
P/S ratio
0.03x
EPS (TTM)
$0.54
Dividend yield
0.62%
52W range
$12 – $16
Volume
2.5M
WallStSmart proprietary scores
48
out of 100
Grade: C
Sell
Investment rating
4.0
Growth
C7.5
Quality
B+5.5
Profitability
C+5.0
Valuation
C+2/9
Piotroski F-Score
Weak
3.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$14.19
+5.66%
12-Month target
$13.43
+0.00%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy2 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.18 — safe zone
+ Free cash flow $10.75B — positive
+ Debt/equity 0.21x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Revenue declining -11.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $245.88B | $279.16B | $325.54B | $353.47B | $335.93B |
| Net income | $45.07B | $55.68B | $56.54B | $45.09B | $2.24B |
| EPS | — | — | — | — | $0.54 |
| Free cash flow | $40.01B | $18.00B | $12.03B | $32.10B | $10.75B |
| Profit margin | 18.33% | 19.95% | 17.37% | 12.76% | 12.80% |
Peer comparison
Smart narrative
Dr. Reddy’s Laboratories Ltd ADR trades at $13.43. representing a P/E of 24.76x trailing earnings. Our Smart Value Score of 48/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 3.18, it sits in the safe zone. TTM revenue stands at $335.93B. with profit margins at 12.80%.
Frequently asked questions
What is Dr. Reddy’s Laboratories Ltd ADR's stock price?
Dr. Reddy’s Laboratories Ltd ADR (RDY) trades at $13.43, on a P/E of 24.8x and a P/S of 0.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Dr. Reddy’s Laboratories Ltd ADR overvalued?
Dr. Reddy’s Laboratories Ltd ADR carries a Smart Value Score of 48/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Dr. Reddy’s Laboratories Ltd ADR (RDY)?
The 12-month analyst consensus target is $14.19, about 5.7% above the current $13.43. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of RDY by 2030?
Our research-backed model puts the 2030 base case at $20.95, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Dr. Reddy’s Laboratories Ltd ADR's revenue?
Dr. Reddy’s Laboratories Ltd ADR's trailing twelve-month revenue is $335.93B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Dr. Reddy’s Laboratories Ltd ADR's Altman Z-Score is 3.18, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.03x
ROE11.60%
Beta0.26
50D MA$13.36
200D MA$13.89
Shares out0.83B
Float3.59B
Short ratio—
Avg volume2.5M
Performance
1 week+0.00%
1 month+1.26%
3 months-5.35%
YTD-2.92%
1 year—
3 years—
5 years—